Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
10.12.2022 - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data from the Company’s ongoing Phase 1 study of ...
ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL, as of December 5, 2022 data-cut date100% ORR and CR rate in 5/5 anti-CD19 autologous chimeric antig...
DUBLIN--(BUSINESS WIRE)--The "CAR-T Cell Therapy Market by Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2022-2035" report has been added to ResearchAndMarkets.com's offering.Cancer is the one of the leading cause of deaths, globally. In fact, as per the World Health Organiza...
01.12.2022 - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on November 30, 2022. Three individuals hired by ...
U.S. stocks closed mostly lower on Wednesday, with the Nasdaq Composite dropping around 175 points. Here is the list of some big stocks recording ...